Finance ❯ Corporate Finance ❯ Mergers and Acquisitions ❯ Valuation

Shareholder Value

Biogen to Buy Apellis for $5.6 Billion in Cash, Adding Syfovre and Empaveli

Biogen aims to use Apellis’ marketed complement drugs to speed its pivot into immunology and nephrology.

Warner Bros. Discovery Board Urges Shareholders to Reject Paramount Bid, Backs Netflix Deal